Comprised Of Two Divisions
Pharmaceutical Division – PhytoPain Pharma
- A new subsidiary created June 2, 2016. 80% Ownership
- Mission is the development and commercialization of botanical based pharmaceuticals
- A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases
Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs
- Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
- 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products
WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS
- A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
- Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
- The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products
PRODUCT PIPELINE
Insomnia Management For Patients With Chronic Pain
- Licensed a hypnotic drug from Mondias Naturals Inc
- Management of Insomnia in patients with chronic pain
- Currently in late stage Phase III clinical testing
PhytoPain To Produce A Combination Product
- Proprietary combination expected to reach Phase I clinical testing in 2017
- Will be ready for market in 2017 due to combination with Mondias Naturals product
Pain Management – Inhalation Cannabis Drug Product
- A prescription drug for management of uncontrolled pain in cancer patients
- Health Canada will provide guidance during Phase I clinical trial
- Commencing December 2016. Anticipating 3-5 year product development
A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.
OPERATIONS OVERVIEW – MMPR
MMPR Division – Collaboration Agreement
- March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producerâ€
- Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
- Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
- Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller
Hub On AGORACOM /Corporate Profile
Tags: #smallcapstocks, $TSXV, medical Marijuana, Medical Marijuana stocks